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Abstract
The gut microbiota and its metabolites  namely short chain fatty acids (SCFAs)  interact
with the digestive, immune, and nervous systems. Microbiota with disrupted composition are
highly associated with obesity, gastrointestinal symptoms, and chronic inammation. Levels
of SCFAs in the feces can represent dynamics of the microbiota and represent one mechanism
by which the microbiota interacts with its host. This study aimed to further our understand-
ing of associations between microbiota bacterial diversity and SCFAs, immune markers, BMI,
and GI symptoms and to identify bacteria that are dierentially abundant in dierent BMI
groups and with synbiotic supplementation. Data (SCFAs, immunoglobulins, body mass in-
dex, fecal ber, fecal protein, measures of GI symptoms, and 16s RNA sequences, n=11) was
extracted from a randomized control trial investigating the eects of synbiotic supplementation
in non-celiac gluten-sensitive participants. QIIME2 was used to process 16s RNA data, analyze
quantitative, qualitative, phylogenetic quantitative, and phylogenetic qualitative measures of
alpha and beta diversity and to perform an analysis of composition of microbiomes (ANCOM)
for identication of dierential abundances. Multiple metrics of alpha diversity were found
to signicantly correlate with IgG4, IgM, IL-2, acetate, propionate, isobutyrate, valerate, iso-
valerate, caproate, heartburn, urgent need to defecate, and feelings of incomplete evacuation.
Multiple metrics of beta diversity were signicantly dierent between normal and overweight,
normal and obese, and overweight and obese BMI classication groups. Beta diversity was
also found to signicantly correlate with IgG1, IgG3, IgG4, IgA, IL-6, IL-8, fecal ber pro-
pionate, butyrate, heartburn, acid regurgitation, nausea and vomiting, bloating, abdominal
distension, increased gas, and eructation. The synbiotic intervention did not signicantly al-
ter alpha or beta diversity. An ANCOM identied bacterial taxa dierentially abundant with
BMI shifts and synbiotic supplementation, though these taxa were not those included in the
synbiotic. Findings demonstrate alpha and beta diversity associations with various SCFAs,
GI symptoms, immune markers, and BMI, and the results of the placebo-controlled interven-
tion suggest careful consideration of placebo contents moving forward. This research supports
plans to apply analysis to larger sample sizes to elucidate changes microbial proles that are
associated with clinically relevant biomarkers and symptoms.
1 Background
1.1 Microbial Communities
Most locations on earth harbor communities of microbes referred to as microbiomes [1]. The
organisms that make up microbiomes are referred to as the "microbiota", though the terms
"microbiome" and "microbiota" are generally used interchangeably [2, 3]. Microbiomes are by no
means new, as the fossil record shows evidence of microbial communities existing over 3.4 billion
years ago [4]. Though much research is primarily focused on microbe-metazoan reactions,
microbial communities started with simply microbe-microbe interactions that are still persistent
today. Some examples include competition for nutrient uptake, secretion of extracellular enzymes,
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secretion of antimicrobial peptides, horizontal gene transfer, parasite transfer, quorum sensing,
and cross-feeding [5]. These interactions create a dynamic yet homeostatic local community
ecosystem, or a 'supra-organism' as some have termed it, and successful microbiomes are resilient
to disturbances, such as colonization from invasive pathogens [6, 5].
Microbiomes are resilient as a result of functional diversity and functional redundancy [5].
Whereas diversity can generally be measured by the number of dierent phyla or genes present,
functional diversity involves the range of traits encompassed by the organisms present in an
ecosystem, such as the abilities to x nitrogen, change the local pH, or produce antimicrobial
peptides [7]. Functional redundancy, on the other hand, is the redundancy of species able to
perform those certain tasks, so if the environment changes and one species suers trauma or
becomes extinct, another can take its job to maintain the health of the ecosystem [5]. Due to the
co-dependence of resilience on both functional diversity and redundancy, a balance between the
orthogonal qualia evenness and richness benet community stability [8]. Evenness is a measure of
how evenly species are distributed, independent of how many species are present, such that having
10 organisms of species A and 2 organisms of species B would be less even than 5 organisms of
species A and 5 organisms of species B, and richness is a measure of how many taxa are present,
where having 5 organisms of species A and 5 organisms of species B would be less rich than
having 1 organism of species A, B, C, D, and E [7]. Functional evenness, or the evenness of
species able to perform certain functions in microbiomes, is positively correlated with community
stability, it yields functional redundancy to stabilize the community in the case of trauma [7].
Likewise, functional richness increases the functional diversity of a community [7]. Though the
relationship between richness and evenness on a spatial scale has not been fully elucidated in
commensal microbiomes, ecological research suggests that on a small spatial scale, richness and
evenness are inversely correlated, but when the spatial scale increases the negative relationship
vanishes [9]. This is likely related to the functionality of taxa interacting with environmental
conditions, as the abundance of certain resources or lack of antagonist factors (such as predators)
in one area may lead to increased proliferation of certain taxa over others [9]. Despite the lack of
research on the relationship between evenness and richness in commensal microbiomes, research
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does demonstrate dierences in the alpha diversity in dierent locations of murine colon [10].
Just as individual microbes in communities interacted with each other via the release and
detection of signaling molecules, evolving eukaryotes also interacted with the preexisting microbes
in their communities [11]. One main example of this is the incorporation of Alphaproteobacteria as
mitochondria in almost all known eukaryotic cells [12]. Another is the theory that the innate
immune systems of vertebrates evolved as a response to microbiomes [13]. Additionally,
interactions between microbial communities and eukaryotes were crucial to the evolution of early
vertebrates, and physiological responses to microbiota have been evolutionarily conserved such
that all species of vertebrate today exist with multiple microbiomes [14]. Homo sapiens, for
example, have microbiota identied in locations primarily including but not limited to the skin,
vagina, and gastrointestinal tract [15]. These microbiomes, like others found in nature, are
dynamically homeostatic: inter-microbiome variation is greater than temporal variation within a
single microbiome [16]. Microbiomes in dierent locations, such as the ear, skin, vagina, and feces,
have their own unique signatures, and most microbiomes from the same location are dominated
by the same groups of bacteria [17]. However, high inter-microbiome diversity is not limited to
microbiomes in dierent locations on the body, as the variance between in the same location of the
microbiome between individuals (e.g. two gut microbiomes in dierent individuals) is greater than
the temporal variance within each of those microbiomes [16]. Due to the consistent and generally
temporally undeviating nature of these microbiota, vertebrate physiology has evolved to rely on
certain functions of the microbiota. This can be largely evidenced by the signicant physiological
disruptions - such as altered metabolism, dysfunctional immune systems, increased inammation,
vascular remodeling, and neurological issues - experienced by germ-free vertebrates [18, 19].
1.2 The Human Gut Microbiota
The largest microbiota of Homo sapiens, the gastrointestinal, or 'gut', microbiota has a mass
equivalent to roughly 2% of the adult body mass, and there are 150 times more unique bacterial
genes present in a standard human host microbiota than there are genes present in the human
genome [20, 21, 22]. This gut microbiome contains an estimated 1014 microbial cells and at least
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1015 viruses [23, 24]. Like other vertebrates, the human gut microbiota has a very important role
in regulating health and disease, and it has been the focus of a large body of research [17]. The
gut microbiota is provided resources by undigested food (largely plant ber) that makes it to the
colon, and the microbes break down or alter these bers to produce metabolites by which they
can interact with the host body [25]. A primary metabolite that will be discussed is short chain
fatty acids (SCFA).
1.2.1 Development of the Human Gut Microbiota
Though there is controversy around evidence for the subject, a developing human is believed
to be exposed to microbes starting as early as fertilization, when egg may be exposed to microbes
from the uterine cervix, from the vagina, or from semen, even in the case of in-vitro fertilization
[26, 27]. Early microbial exposure from the endometrial microbiome is also believed to aect
implantation via the immune system, as inammatory responses to microbiota will compromise
the success of implantation [28, 29, 30]. In theory, the prevention of implantation of a fertilized
egg in the case of an inammatory uterine microbiota may prevent the development of
maladapted immune system [27]. Despite the stigma of the sterile womb dogma, evidence that the
implanted embryo is exposed to microbes through the placenta and amniotic uid dates back to
1927 and has been replicated multiple times through both metagenomics-based and
non-metagenomics-based methods [27, 31, 32, 33]. The microbiome of the placenta, which ideally
contains non-pathogenic microbes, is low in abundance but rich in metabolic diversity, and it
exhibits a prole more similar to that of the oral microbiome than to the vaginal microbiome [33].
Other than direct transmission from the vaginal microbiota, there are multiple proposed methods
as to how microbes translocate to the placenta, including migration from the gastrointestinal tract
and migration from the oral microbiota. Mouse models have shown translocation of bacteria from
the gut microbiota to the placenta, and there are mechanisms by which oral microbes and
periodontal pathogens may enter the bloodstream and spread to the placenta [34, 35, 36].
Hematogenous spread (through blood) of oral microbes to the placental microbiota may be a
potential mechanism by which of periodontitis can impact preterm birth [37]. The eect of
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periodontal pathogen translocation does not appear to occur by directly changing the composition
of the placental microbiome but by altering the behavior of typically benign microbes to become
more pathogen-like [37]. Interestingly, the placental microbiome correlates less with obesity and
metabolic factors of the mother than it does with frequency of antenatal infections including lower
urinary tract infections, pyelonephritis, and sexually transmitted infections such as Neisseria
gonorrhea and Chlamydia trachomatis, which could be a result both of treatment with antibiotics
and the resilience of pathogens [33]. For example, Escherichia coli, which is common in both lower
urinary tract infections and pyelonephritis, can bind to uroplakins to evade immune detection and
therefore remain present within the host body until opportune chances to recolonize arise [38].
Maternal environmental microbial exposure, including exposure to farmland during pregnancy,
also modulates the placental microbiome and is recognized as a predictor of health throughout the
lifespan [39]. Though research supports a positive correlation infection by pathogenic bacteria
with preterm birth, it has been dicult thus far to characterize what a 'healthy' pregnant uterine
microbiota should contain due to the existing (yet changing) dogma of the sterile womb and
technical and ethical issues of sample collection during pregnancy [27, 40]. Despite the
controversy surrounding the concept, it can be concluded that bacteria are present in amniotic
uid without cases of infection or adverse outcomes, and colonization by non-pathogenic bacteria
in the placenta can program the fetus's metabolic pathways and immune system through stepwise
microbial exposure, making it more resilient against pathogenic microbes that may contribute to
adverse outcomes before or shortly after birth and even throughout the lifespan [41].
The rst two years of life comprise an incredibly important window of opportunity for
colonization and immune modulation, and primarily starting when the newborn is exposed to a
large abundance of microbes from the mother's vaginal canal and the environment at birth [36].
Despite theories that lasting colonization of the gut microbiota begins at birth, analyses of
microbiota from the meconium, placental, amniotic uid, and colostrum in mother-infant pairs
provide evidence that colonization begins before birth and that placental microbiota may be more
inuential on the development of the meconium microbiota than the delivery method [39, 42].
However, as a newborn matures, microbial exposure from the vaginal canal, from the
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environment, and from food has a larger eect on the gut microbiota than pre-delivery exposure,
and the structure of the gut microbiota shifts toward representing that of a fully developed human
[41, 43]. At 6 days post-delivery, gut microbiota dierences between vaginal and caesarian-section
delivery methods are evident. The gut microbiota of vaginally delivered infants resembles that of
the mothers vagina, as it was the rst exposure to microbes at birth, whereas the gut microbiota
of caesarian-section delivered babies more closely resembles the microbiota of the mother's skin
and environment [44, 43]. In a newborn's early life, breast milk - especially colostrum - which is
rich in diverse oligosaccharides, provides support for bacterial growth within the colon [34].
Human milk oligosaccharides (HMOs) are not degraded by the infant, and their structures are
specic to degradation abilities of certain bacteria regarded as being immunoregulatory, such as
Bidobacterium longus subsp. infantis [34, 45]. Immunoregulatory bacteria can improve stress
resilience through the brain-immune axis during the highly stressful period of time around birth
via multiple mechanisms including normalization of the interleukin-6 (IL-6) response to stress and
increase in regulatory T cell levels [46, 47]. Prebiotics in breast milk also serve an antimicrobial
role against certain pathogens such as group B Streptococcus and Candida albicans, and they
protect against pathogen colonization by supporting the development of high levels of microbial
richness in a child's microbiota [34]. As the composition of breast milk changes and a child is
exposed to new pathogens, the diversity of the gut microbiota increases, yet it retains high
abundances of certain colonizing bacteria [43, 34]. Around 2 to 3 years of age, an individual's
unique microbial phenotype becomes relatively established, and sequencing methods show that
the gut microbiota of healthy children tends to have higher levels of Bidobacterium, certain
strains of Escherichia coli, Faeacalibacterium prazsnitzii, and Lactobacillus than the gut
microbiota of children with diseases such as infection, necrotizing enterocolitis, diabetes, and
inammatory bowel diseases [34, 48].
As an individual matures and the gut microbiota becomes established, multiple studies have
demonstrated that the dominant bacterial species shift from Actinobacteria and Proteobacteria to
Firmicutes and Bacteroidetes in individuals with low disease burdens [49]. In adulthood,
individuals have highly variable microbiota dependent on diet, travel, illness, hormone cycles, and
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genetics, though genetics are a lesser inuence than the other aforementioned factors, as
evidenced by studies demonstrating that identical twins share only 50% of their microbiota
[49, 50, 51]. Though a healthy adult microbiota is rich in Firmicutes and Bacteroidetes, acute and
chronic trauma to the microbiota via antibiotic use, poor diet, or chronic stress can alter this
balance [51, 52]. This altered balance can include decreasing the abundance of Bacteroidetes and
Firmicutes, decreasing the Firmicutes to Bacteroidetes ratio, increasing the abundance of
Proteobacteria, and decreasing the richness of the microbiota [51, 52]. All of the aforementioned
changed tend to be associated with chronic inammatory diseases. Unfortunately, altered gut
microbiota associated with poor health, referred to as dysbiosis, creates shifts in host physiology,
such as hyperactive stress responses, that perpetuate the dysbiotic state [52]. Dysbiosis, however,
should not be characterized using any specic denition based on microbiota diversity or
abundances nor as the binary opposite of eubiosis: variability in microbiota are not such that
certain characteristics make the host more or less healthy in all areas of the world, disease states,
or ages [53]. Thus, referring to dysbiosis as a specic microbial signature detached from specics
such as host health metrics, demographics, and age is misleading, and more appropriate means of
alluding to dysbiosis include referring to the microbiota as trending toward known dysbiotic
factors (given known host health factors), referring to the microbiota compared to a control (not
'healthy') group with similar characteristics, or a combination of both. Though much research
exists regarding dysbiotic states, one must consider its limitations and not overreach into
attempting to dene globally healthy and unhealthy microbiota or hosts solely based on
microbiome data. A key example cited by Brussow is that bottle-fed infants have greater gut
microbiota alpha diversity than breast-fed infants, yet this does not translate to greater health
outcomes [53, 54].
1.2.2 Host-Microbiota Interactions
Through mechanisms outlined in the Layered Hygiene Hypothesis and the Old Friends
Hypothesis, stepwise exposure to microbes throughout the rst few years of life aects disease risk
throughout the lifespan via exposure to immunoregulatory microbes and establishment of certain
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microbial phenotypes that aect pathogen colonization and stress resilience [55, 56, 57].
Inammation associated with the immune activation that can be triggered by the gut microbiota
plays multiple roles in various diseases including but not limited to inammatory bowel disorders,
metabolic syndrome, and psychiatric disorders [58, 59, 60, 61]. There are multiple mechanisms by
which this occur, such as through antigen exposure, gene exposure, and peptide production, but
one primary mechanism is the fermentation of dietary bers to produce short chain fatty acids
(SCFAs) ranging from 2 to 6 carbons in length [62].
1.2.2.1 Fibers: from the host to the microbiota
Since the human digestive system only produces roughly 17 gastrointestinal enzymes, and
carbohydrates can only be absorbed as monosaccharides at the brush border of the small intestine
through SGLT1 and GLUT5 transporters, many plant bers and lignins with complex structures
completely or partially escape digestion [63, 64, 65]. These complex plant bers are dened as
dietary bers by the CODEX Alimentarius Commission as carbohydrates with lengths over 10
monomeric units that are not hydrolyzed by the enzymes endogenously present in the small
intestines of humans. Some denitions of dietary bers, such as those by the Australian,
Canadian, and New Zealand food standards and public health groups include carbohydrates as
short as 3 monomers in length [65, 66]. The overarching concept of dietary bers is that they are
not digested by the endogenously produced human enzymes by the time they leave the small
intestine, and there are many types of dietary bers that vary based on the species of plant from
which they originate [67, 65]. Most dietary bers are prebiotics, or particles that are resistant to
gastric acid in the stomach and hydrolysis in the small intestine and that are fermented by the
gut microbiota, stimulating the growth of non-pathogenic bacteria; however, not all dietary bers
are prebiotics, and not all prebiotics are dietary bers [65]. Dietary bers can be categorized into
soluble and insoluble bers based on their solubility in water, and these bers can have laxative or
constipating eects based on their structures and viscosity (if soluble) [67]. Dierent ratios and
abundances of each type of dietary ber can eect the composition of the microbiota by
modulating the amount of time that resources are available in the colon and the frequency by
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which microbes are removed from the colon during luminal washout [67, 68, 69]. Insoluble bers
with large, course particle sizes irritate the gut mucosa, causing a laxative eect, whereas viscous
soluble bers slow gut transit and help to normalize stool consistency [67]. Fast colonic transit is
associated with higher abundances of bacterial species such as F. prausnitzii that are associated
with a healthy mucosal barrier and decreased low-grade inammation, and slow colonic transit is
associated with a more methanogenic prole, higher bacterial protein catabolism, increased
mucosal degradation by bacteria, and other factors trending toward dysbiotic factors [69].
However, stool transit being too fast will result in increased ushing of microbes and potential
disruption of the microbial environment, insoluble bers are poorly fermented by the microbiota,
and viscous soluble bers have non-microbiota-mediated health benets, such as trapping bile,
which lowers cholesterol levels, so it is important to have a balance of soluble and insoluble bers
[67, 70, 71]. Non-viscous soluble bers, such as resistant starches, which are long strains of
amylose-like digestible carbohydrate that cannot be fully degraded in the small intestine due to a
lack of time rather than a lack of enzyme functionality, function as rapidly fermentable prebiotics
for the microbiota [67].
1.2.2.2 Short chain fatty acids: from the microbiota to the host
Once dietary bers and resistant starches reach the colon, they are fermented by bacteria to
produce SCFAs including acetic acid, propionic acid, butyric acid, valeric acid, and caproic acid
[72]. Branch-chain isomers of SCFA (BSCFA) including isobutyric acid, 2-methyl butyric acid,
and isocaproic acid are not produced by ber fermentation. Instead, they are products of
bacterial metabolism of valine, leucine, and isoleucine [72]. These acids are assumed to be in the
deprotonated form in the colon and are therefore referred to with the -ate sux (e.g. butyrate).
In healthy individuals, acetate, propionate, and butyrate constitute 95% of the SCFAs produced,
and they are produced in a ratio of 60:20:20, respectively [62, 73]. The general stoichiometry for
the fermentation of carbohydrate to produce SCFA is 59 C6H12O6 + 38 H2O → 60 CH3COOH +
22 CH3CH2COOH + 18CH3CH2CH2COOH + 96 CO2 + 268 H+ + heat + additional bacteria
[74]. Roughly 95% of SCFAs produced are absorbed, and they make up almost 10% of the energy
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requirements of humans [62]. Though only about 5% of the SCFA produced are excreted, SCFA
research has focused on fecal SCFAs due to the impracticality of measuring colonic SCFAs [76].
Findings suggest that fecal SCFA ratios - but not the amounts passed in the feces due to varying
SCFA absorption rates between individuals - are representative of colonic production, and ratios
between the SCFAs correlate with health and disease states [75, 76]. SCFAs decrease the luminal
pH of the colon, decreasing the solubility of bile salts, increasing mineral absorption, and altering
the microbiota, inhibiting pathogen growth [77, 78].
As acetate is able to escape metabolism in the liver, it makes up the highest proportion of
SCFA in systemic circulation, though there are multiple factors confounding this data, such as the
endogenous production of acetate [72, 77]. Outside of microbiota research, acetate is known as a
source for central carbohydrate metabolism when nutrients are limited, and it is used as a parallel
pathway for acetyl CoA production [79]. Additionally, emerging research suggests that the de
novo source of acetate in mammals is from conversion of pyruvate via coupling to reactive oxygen
species and via the activity of alpha-keto dehydrogenases [79]. Acetate is produced from the
fermentation of acetogenic bers such as inulin and galacto-ligosaccharides primarily in the
proximal colon, but it can also be produced by fermentation of peptides and fats in the distal
colon [80]. Due to acetate's ability to be produced by the fermentation of fats and nitrogenous
compounds, fecal and serum acetate percentages are increased by high fat diets (HFDs) [80].
Higher acetate production is associated with an increased Firmicutes/Bacteroidetes ratio, which
tends to correlate with a dysbiotic state and negative health outcomes [80, 81]. Through increased
parasympathetic activity mediated by the vagus nerve, acetate increases glucose-stimulated
insulin secretion via the microbiota-β-cell axis, and it triggers the release of ghrelin, a peptide
that regulates appetite (among other roles) and is commonly referred to as the 'hunger hormone'
[81, 82]. The combination of these two promotes metabolic syndrome by promoting hyperphagia
(increased hunger from ghrelin), hypertriglyceridemia, and increased fat storage [81, 82]. Long
term upregulation of insulin secretion due to acetate is thought to contribute to insulin resistance
and metabolic syndrome [77]. Due to its ability to be converted to Acetyl-CoA, acetate can
promote cholesterol synthesis and lipogenesis [77, 83]. 50-70% of acetate is metabolized in the
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liver, where it can contribute to non-alcoholic fatty liver disease (NALFD) in the case of elevated
acetate levels, and the rest is oxidized by muscle tissue [77, 84, 85]. Acetate is also produced by
acetogens that can consume H2 for energy and release methane, acetate, and H2S as end
products, increasing the ability of NADH to be reoxidized to NAD+ [86]. Primary fermentation is
generally limited by the buildup of H2 and reducing equivalents inhibiting reoxidation of NADH,
so acetogens increase the eciency of fermentation by consuming H2 [87]. Decreased inhibition of
primary fermentation leads to increased SCFA production and therefore increased energy
contribution to the host, promoting obesity [86].
Unlike acetate, propionate is unable to bypass the liver, so it thus makes up a lower proportion
of the SCFA in circulation [72]. Propionate in the liver is used for gluconeogenesis, and it inhibits
hepatic lipogenesis and cholesterol synthesis via inhibiting HMG CoA reductase [77, 72, 88].
Propionate can trigger intestinal gluconeogenesis through a mechanism dependent on G
protein-coupled receptor GRP41 and through the gut-brain axis [89, 90]. Propionate is produced
through the xation of CO2 to form succinate and from lactate and acrylate via the acrylate
pathway, and it it incredibly important for gluconeogenesis in ruminants [77]. On the grounds of
immunomodulation, propionate can trigger increased extra-thymic de novo production and
dierentiation of Treg cells, which has an anti-inammatory and anti-metabolic syndrome eect
via regulating the TH1/TH2 ratio in the body and other immunosuppressive measures
[91, 92, 93]. Treg cells play an important role in staving the pathogenesis of autoimmune disorders
and allergies in addition to gut disorders, such as inammatory bowel disease, Crohn's disease,
and ulcerative colitis, suggesting a role of propionate in preventing gastrointestinal disorders,
especially those linked to eosinophilic and autoimmune reactions [94, 95]. Another suspected
mechanism for immunosuppression by propionate (as well as butyrate) is its ability to bind to
GPR41 and GPR43 which are common in mammalian immune cells, but specic anti- or
pro-inammatory eects of these receptors are not well understood [96, 97]. Propionate, in a pH
under 5, can kill pathogenic E. coli and Salmonella, protecting the epithelium from colonization
[98]. Another means by which propionate protects the gut epithelial border is by supporting
apoptosis of colonocytes [75].
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Butyrate serves as the major substrate for energy production in the ceco-colonic epithelium,
and a lack of butyrate leads to autophagy due to increased intermediary metabolism, not solely
due to its role as a histone deacetylase (HDAC) inhibitor as previously thought [77, 85, 99]. The
colonic epithelium is highly inuenced by butyrate, as its absence triggers rapid and overactive
autophagy, and abundance triggers apoptosis of tumor cell lines [75]. Additionally, butyrate
inhibits tumor necrosis factor-α and interleukin 13 to aect the expression of proteins that
regulate structure of colonocyte tight junctions [100]. Poor tight junction structural integrity is
thought to lead to intestinal permeability, immune hyperactivation, chronic inammation, and
risk of metabolic diseases [101]. The mammalian gut exists in a state of relative hypoxia, and the
microbial production of butyrate decreases colonocyte oxygen consumption, stabilizing the
transcription factor hypoxia-induced factor-1 (HIF-1), which performs epithelial barrier-enhancing
functions, again protecting against colitis and chronic diseases [102]. Butyrate inhibits the
production of nuclear factor kappa-B (NF-kB), which is highly active in regulating systemic
production of inammatory cytokines that are active in the immune-brain axis and the
development of major depressive disorder [103, 104].
Other SCFA are not as well studied as acetate, propionate, and butyrate, but they are still
relevant to health maintenance. Valerate (also referred to as pentanoate), like butyrate,
suppresses autoimmune pathologies by inhibiting HDAC and therefore downregulating IL-17
production in CD4+T lymphocytes [105]. Valerate, unlike butyrate, does not alter the production
of Treg cells, demonstrating dierent mechanisms of action in immunosuppression between them
[105]. In mouse studies, valerate has shown to mediate regulatory B cells protecting against
autoimmune disorders [105]. Valerate has also demonstrated ability to impair growth of
Clostridioides dicile and E. coli in the gut [106, 107]. Increased valerate and caproate levels are
associated with increased richness and high abundances of Prevotella and Coprococcus [108].
1.3 Microbiome Analysis
Since a large fraction of bacteria present in the microbiota have yet to be reliably cultured
successfully, microbiomes are primarily analyzed via sequencing of the RNA present in the feces
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[109]. The 16S ribosomal RNA subunit appears to be conserved across most bacterial species, so
it has become useful tool to analyze a representation a microbiota sample's structure [110, 111].
However, the so 16S rRNA subunit is too long (1400 base pairs) to be sequenced in one read with
the current technology available in a cost-ecient manner, but it can be broken into
hyperconserved and hypervariable regions that are short enough to be read by systems such as
Illumina's HiSeq and MiSeq (capable of less than 250 base pairs at a time) [112, 113]. The
conserved regions can be used as 'anchors' to denote the loci of 8 variable regions, allowing for
sequencing of variable regions to create identiers for dierent taxa present in the sample[112].
Polymerase chain reaction primers can be designed based on the conserved regions to sequence
specic variable regions via next-generation sequencing [112]. However, based on dierent
variability seen in certain variable regions of specic microbiomes, some variable regions are better
suited for analyzing certain microbiomes, such as gut or soil though using these variable regions
may promote specic biases, shifting the observed taxa to misrepresent what is actually present
[114, 113]. More variable regions can be sequenced to provide higher accuracy, but the cost, time,
and computational resources increase with the number of base pairs sequenced, so one must
acknowledge the trade o made between cost and accuracy (including the inherent biases present
based on variable region sequenced) [115, 116]. Though researchers with more resources may use
more variable regions, sequencing the V4 variable region via 515f/806r primers per the Earth
Microbiome Project 16s Illumina Amplicon Protocol has emerged as a popular and standardized
approach across various projects including the American Gut Project, the Human Microbiome
Project, the Flemish Gut Flora Project, and the Sponge Microbiome Project
[17, 117, 118, 119, 120].
1.3.1 Using QIIME2 for Microbiome Analysis
Data generated from 16s sequencing is large and complex, and it must be analyzed using
computational methods. One program used to do so is Quantitative Insights Into Microbial
Ecology 2 (QIIME2), a decentralized and open-source microbiome analysis software package that
allows for transparency via data provenance tracking [121]. A typical workow in QIIME2
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involves demultiplexing sequences, removing likely misreads (or 'noisy' sequences), and
dereplicating sequence reads (while maintaining a count of sequences present) to decrease the
amount of data that must be to processed [121, 122]. The QIIME2 denoising plugins DADA2 and
Deblur check for chimeras, such as mitochondrial rRNA sequences that might pollute samples,
and they cluster similar sequences into operational taxonomic units (OTUs) with their frequencies
stored in feature tables [122, 123, 121]. Once OTUs are generated, they can be assigned taxonomy
by a machine learning classier (such as a Naïve Bayes classier) trained on 16s databases, such
as SILVA or GreenGenes [124]. Naïve Bayes classiers have shown reliable ecacy for assigning
taxonomy, and they are based o Bayes' Theorem for conditional probability stating the following:
P(A|B) =
P(B|A) × PA
PB
In this equation, PA represents the probability of a certain taxonomic classication being true,
and PB represents the probability of the sequence data being true. A Naïve Bayes classier will
identify the most likely taxonomic classication, given the sequence data and database provided.
Additionally, QIIME2 plugins create a pipeline for aligning sequences and for generating rooted
and unrooted phylogenetic trees that can be visualized or used for diversity analyses [125].
Diversity analyses in QIIME2 can be run individually through a core diversity pipeline, and
multiple measures of alpha and beta diversity can be tested, and emperor plots can be generated
to demonstrate dierences in microbial communities [121]. QIIME2 also includes a variety of
other more specialized plugins such as supervised and unsupervised machine learning sample
classiers that have successfully predicted cancer and wine quality [126, 127].
1.3.2 Diversity Measures
Understanding the diversity measures claries the information provided to the researchers and
the limitations of each measurement. Alpha diversity, or the diversity within a sample, is
commonly measured using Shannon's diversity, observed OTUs, Faith's Phylogenetic diversity,
and Pielou's Evenness. Common measures of beta diversity, which is the diversity between
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samples, include Jaccard, Bray-Curtis, unweighted UniFrac, and weighted UniFrac. Diversity
measures can be classied as phylogenetic/nonphylogenetic and qualitative/quantitative.
Qualitative measures of diversity simply focus on the number of dierent taxa focused, whereas
quantitative measures place weight on the number of each taxa present.
1.3.3 Alpha Diversity
Observed OTUs is the easiest to calculate, as it, a nonphylogenetic, qualitative measure, is
simply a total of the number of OTUs present in a sample. Shannon's diversity index (H), which
is quantitative and nonphylogenetic, is calculated as:
H = −
S∑
i=1
piln(pi)
Here, pi is the proportion of population the population constituted by OTU i, and S is the total
number of OTUs present [128]. Faith's phylogenetic diversity is phylogenetic and qualitative, and
it is the sum of all the lengths of the branches of the phylogenetic tree for a community [129].
Pielou's evenness (J ′) is not a measure of richness but a measure of evenness [130]. It can be
calculated as:
J ′ =
H ′
H ′max
Here, H ′max is the max possible value of Shannon's diversity index for the given population (which
assumes only one organism per species S, so Pi = 1S ) and can be calculated as:
H ′max = −
S∑
i=1
1
S
ln
(
1
S
)
(1)
H ′max = −S
(
1
S
ln
(
1
S
))
(2)
H ′max = −ln(S−1) (3)
H ′max = ln(S) (4)
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Thus:
J ′ =
H ′
ln(S)
1.3.4 Beta Diversity
Jaccard distance is a nonphylogenetic qualitative measure of community similarity, and it can
be written as:
JA,B = (A ∩B)/(A ∪B)
Here, A is one sampled community, and B is another sampled community, such that the Jaccard
distance is the number common OTUs divided by the total number of OTUs in observed in the
two samples [131]. Bray-Curtis distance is a nonphylogenetic quantitative measure of community
dissimilarity, where the dissimilarity D between samples A and B is:
DA,B =
∑S
i=1 |nAi − nBi|
nA+ + nB+
Here, nAi is the abundance of OTU i in sample A, and nA+ is the total of all species abundances
in sample A [132, 133]. As Bray-Curtis is the dierence in species abundances divided by the total
abundances, it is limited by the assumption that both samples contain a similar abundance and
occupy a similar physical area or volume [132]. UniFrac distances are used to analyze phylogenetic
dierences between two samples [134]. Unweighted UniFrac is qualitative and thus does not place
'weight' on the abundance of each taxa present, and it (u) for communities A and B can be
calculated as:
uA,B =
S∑
i=1
bi
bt
3 i = A4B, t = A ∪B
In this equation, bi is the length of branch i that is not shared in communities A and B, and bt is
the length of all branches in A and B individually [134]. To calculate a raw weighted UniFrac
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value (w) for communities A and B:
wA,B =
S∑
i
bi ×
∣∣∣∣AiAt − BiBt
∣∣∣∣
In this equation, n represents the number of branches, and bi is the length of branch i. Ai
represents the abundance of OTUs descending from each branch i in community A, and it is
divided by At,the total abundance of sequences in community A in order to balance out unequal
sampling [135]. In cases with rapidly evolving taxa, where branch lengths might be highly
variable, branch length is replaced with the sum of the length of the branches from the root to
further normalize branch length values [135].
2 Methods
2.1 Patient Recruitment
Patients (n=20) were recruited through the process outlined in Webb 2019 [136]. Inclusion
criteria for patients included the presence of predened gastrointestinal symptoms at least three
times per week, self-identication as healthy, and age over 18 years. Exclusion criteria included
diagnosis of celiac disease, irritable bowel disorder, inammatory bowel disease (including Crohn's
disease and ulcerative colitis); current consumption of prebiotics, probiotics, enzymes,
non-steroidal anti-inammatory drugs (NSAIDs), sh oil, and/or ber supplementation unless
willing to cease supplementation 2 weeks prior to the study; prescribed use of any NSAID; and
pregnancy or intent to become pregnant within 60 days. Before commencing the study, all
participants were administered an informed consent document. A subset of the participants
(n=11) was used for microbiome analysis. This study was fully approved by the ETSU
Institutional Review Board on December 5, 2017; study number 1117.22f.
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2.2 Study Design
This study was split, partially blinded, and placebo-controlled. Participants were split into two
groups, A and B, by a random number generator. Both groups went through a two-week washout
period, and for the second four weeks (28 days) group A was assigned to take the Glutenshield
supplement 3x daily with meals while group B was assigned to take a placebo 3x daily with meals.
Participants were not informed whether they were given the placebo or control supplement.
Following the two week washout, on day 0 of the active portion of the study, participants arrived
with a stool sample collected 'at home', and two tubes of whole blood were drawn. Participants
completed a survey of gastrointestinal symptoms, and they were given a bottle of 84 Glutenshield
or Placebo pills, dependent upon their assigned group. On day 28 of the active study, participants
returned with a stool sample collected 'at home', gave another blood sample of equal volume, and
lled out the gastrointestinal symptoms questionnaire.
2.3 Supplement Contents
The placebo supplement was a 1:1 mixture (by mass) of microcrystalline cellulose (Avicel) and
bentonite powder. Glutenshield is a synbiotic supplement developed by Shield Nutraceuticals. It
contains the probiotics Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus,
Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus salivarius, Lactobacillus coagulans,
Bidobacterium lactis, Streptococcus thermophilus, Bidobacterium bidum, Saccharomyces
bouldarii ; the prebiotics chitosan oligosaccharide, fructooligosaccharide, alfalfa, Emblica ocinalis
extract, papaya juice powder, fulvic acid, and ionic minerals; and the enzymes dipeptidyl
peptidase IV, lactase, cellulase, hemicellulase, xylanase, phytase, serrapeptase, and plant-based
lipase, protease, and amylase. Both supplements were encapsulated by Vcaps Enteric capsules.
2.4 GI Symptom Questionnaire
The GI symptom questionnaire completed on days 0 and 29 included a Likert numerical scale
that ranged from 1 to 7, with 1 being no symptoms and 7 being constant/severe symptoms, and
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participants were instructed to ll it out based on their symptoms over the past week. The
symptoms indicated on the questionnaire included abdominal pain/ discomfort, heartburn, acid
regurgitation, bloating, nausea and vomiting, abdominal distension, eructation (burping),
increased gas, decreased passage of stools, increased passage of stools (rapid transit), loose stools,
hard stools, urgent need for defecation, and feeling of incomplete evacuation.
2.5 Blood Sample Collection and Analysis
On day 0 and day 29, 10mL blood samples were collected in two 8.5 mL Becton Dickinson
vacutainers. Following collection, the samples were put on ice and brought to ETSU's health
science laboratory, where they were allowed to clot at room temperature for 30 minutes and then
centrifuged at 3000 x g for 10 minutes. After centrifugation, 1 mL of serum supernatant was
transferred to a 1.5 mL polypropylene Fisherbrand micro-centrifuge tube via Eppendorf pipette,
and 2 mL of serum supernatant was transferred to a Fisher Scientic amber vial via Eppendorf
pipette, and the transferred serum was stored at -80◦C until needed for analysis. Analysis of serum
was performed using commercially available ELISA plates from Aviscera Bioscience. ELISAs were
performed to test for IgG1, IgG2, IgG3, IgG4, IgA, IgM, IL-2, IL-6, IL-8, and TNF-α.
2.6 Fecal Sample Collection and Analysis
Upon completion of the informed consent, participants were given multiple sets of supplies and
instructed on how to collect the stool sample using saran wrap placed under the toilet seat.
Samples were to be collected within 24 hours of sample submission (days 0 and 24) and stored in
a freezer in a self-sealing plastic bag. Stool samples were stored on ice in biohazard containers and
transported to ETSU's Nutrition and Dietetics Research Laboratory on the Valleybrook campus.
1 gram of fresh sample was separated and stored at -80◦C for microbiome analysis, and the
remainder was freeze-dried and ground to be used for nutrient and SCFA analysis. Freeze-drying
was performed at 0.077mBar and -50◦C for 48-72 hours until samples were thoroughly dry.
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2.6.1 Kjeldahl Digestion
Total nitrogen was determined for freeze-dried and ground samples using kjeldahl digestion.
For the procedure, 100 mg of the sample was weighed (weight was recorded) into a 100 mL
kjeldahl ask along with 1.9 grams of potassium sulfate (K2SO4), 80 mg of mercuric oxide (HgO),
2 mL of concentrated (10N) sulfuric acid, and 2 porous boiling chips. The sample was placed on
LABCONCO heat mantle. The air was turned on and the mantle was turned to heat setting 3.
The sample reuxed for 8-12 hours, the heat mantle was then turned o, and the sample was
cooled to room temperature. 15 mL of deionized distilled water (DDW) was added to the kjeldahl
ask. The sample was brought to a boil and was ltered while hot into a 150 mL Erlenmeyer ask
using P5 grade Fisher brand qualitative grade plain lter paper circles. Following digestion of the
samples, distillation was performed to determine total nitrogen per sample. The LABCONCO
rapid distillation unit was turned on, set to heat setting of 6-7, and was allowed to heat up. 5mL
of 4% Boric acid and a few drops of kjeldahl indicator were added to a new 150 mL Erlenmeyer
ask. The ask was placed at the bottom of the distillation unit. The distillate (ltered sample)
was added to the top of the unit and the Erlenmeyer ask was rinsed with DDW. The material
was emptied into the reaction tube. 10 mL of sodium thiosulfate (NaOH/ Na2O3S2) was added to
the top of the apparatus and was slowly emptied into the reaction tube. The sample was allowed
to distill for 15-20 minutes until the total volume of the boric acid and ammonium solution
reached 25-30 mL. During the distillation process, ammonium (NH+4 ) was converted to ammonia
gas (NH+3 ). NH
+
3 condensed into the boric acid solution to form ammonium borate. The
ammonium borate was then titrated with 0.1 N HCl until a color change was observed (blue →
red; base → acid). The mL of HCl needed to titrate the solution back to an acid was recorded.
Nitrogen per kilogram of sample and percent total protein were then calculated. Samples were run
in duplicate per participant fecal sample provided.
2.6.2 Fiber Analysis
Total dietary ber (TDF), soluble dietary ber (SDF), and insoluble dietary ber (IDF) was
assessed on freeze-dried, ground stool samples using the automated ANKOM Dietary Fiber
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Analyzer method AOAC 991.43. Reagants included 78% Ethanol by volume, α-amylase
(5mL/25mL DDW), protease (5mL/25mL DDW), amyloglucosidase (5mL/25mL DDW),
MES-TRIS buer, and 0.561N HCl. The MES-TRIS solution was prepared by dissolving 9.76 g of
2-(N-Morpholino)ethanosulfonic acid (MES) and 6.1 g of Tris(hydroxymethyl)aminomethane
(TRIS) in 850 mL of DDW and adjusting the pH to 8.2 using 6N NaOH and dilute to 1 L with
DDW.
ANKOM IDF and SDF lter bags were labeled with a permanent marker. Each bag was
weighed using the Bag Weigh Holder and an AL54 Mettler Toledo analytical balance. The tare
bag weight was recorded onto a Dietary Fiber Data Spreadsheet (DFDS). One gram of
Diatomaceous Earth was weighed into two separate dishes. The weight of each was recorded onto
the DFDS. 0.5±0.05 g of the freeze dried, ground stool sample was weighed in duplicate into two
dishes. The weight of each was recorded onto the DFDS. All uid levels were checked on the DF
analyzer. The instrument and Nitrogen gas were turned on. SDF bags and Clamp Bar D were
installed on the instrument. Clamp Bar D was closed and the pre-weighed DE was added to each
SDF bag and was rinsed with 2-3mL of DI water. IDF bags and Clamp Bars B and C were
installed onto the instrument. Clamp Bar B was closed, pinching o the bags, and the pre-weighed
samples were transferred to the IDF bags. SDF bags were hooked to Clamp Bar C. Clamp Bar A
was installed. The instrument was started, beginning the automated process of digesting the
sample. After the amylase and protease phases, the pH of the samples was checked and adjusted
to 4.0-4.7 as needed with 0.561N HCl. After the automated process was complete, IDF and SDF
bags were rinsed with Acetone using the ANKOM Acetone Rinse Stand. After drying, the bags
were sealed at a heat setting of 3 using the ANKOM Heat Sealer. Samples were placed on a
drying rack and were placed in a Fisher Scientic Isotemp oven at 100◦C for 90 minutes. Samples
were removed from the oven and immediately placed in an ANKOM MoistureStop weigh pouch
(desiccant pouch) to cool. Bags were removed one at a time from the desiccant pouch and were
weighed on an analytical scale using the Bag Weigh Holder. Bag weights were recorded on the
DFDS. A protein correction was performed using kjeldahl digestion and distillation, as described
above. An ash correction was also performed by burning the samples as 700◦C for 5 hours and
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recording the weight after ashing. All ashing and protein values were recorded on the DFDS.
Percent IDF, SDF and TDF were then calculated using the following equations:
%IDF or %SDF =
Total residue− (protein residue + bag)− (ash residue + bag)
original sample weight× 100%
TDF = %IDF+%SDF
2.6.3 SCFA Extraction and Analysis
SCFA extractions were performed using a procedure developed by Schwiertz et al. that was
modied [137]. One mL of the SCFA extraction solution, containing Oxalic acid (0.1 mol/L),
Sodium Azide (40 mmol/L), and Caproic acid (0.1 mmol/L )(internal standard) was added to 80
mg of a freeze-dried stool sample in a 16 x 100 mm disposable culture tube. The tube was capped
and vortexed for 30 seconds. The tube was placed on a horizontal shaker for 1 hour. The tube
was centrifuged at 4000 rpm for 20 minutes. After centrifuging, the supernatant was removed and
placed in a 1.5mL polypropylene Fisherbrand micro-centrifuge tube. The solution was
re-centrifuged at 12,000 rpm for 15 minutes. Again, the supernatant was removed and placed in a
new 1.5 mL micro-centrifuge tube. The solution was re-centrifuged at 12,000 rpm for 15 minutes.
Finally, the supernatant was removed, placed in a 2 mL amber vial, and was stored at -80◦C until
being analyzed using a Shimadzu GC2010 gas chromatograph with SigmaAldrich ZB-Wax Plus
capillary column. Samples were run using a method adapted from Schaefer et al [138]. The
method included injecting 1 µL of solution with an SPL1 temperature of 250◦C. The initial
column temperature was 50◦C, held for 2 minutes, which rose at a rate of 15 degrees/minute until
reaching 140◦C with a hold of 5 minutes, followed by a rise at rate of 10 degrees/minute until
reaching 160◦C with a hold of 3 minutes and a rise of 10 degrees/minute until reaching 175◦C
with a hold of 3 minutes. The ame ionization detector temperature was 180◦C, and the end time
of the run was 24 minutes. Samples were run in duplicate, and values for each participant were
averaged.
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2.7 Microbiome Analysis
2.7.1 16s RNA Isolation and Sequencing
Microbiome analysis was performed on 11 participants in duplicate before and after
intervention for a total of 44 samples sequenced and analyzed. Powersoil DNA isolation kit was
used to isolate DNA from the portion of the fecal samples stored at -80◦C. 250 mg of the sample
was added to the Qiagen-supplied PowerBead tube and vortexed. 60 µL of solution C1 (Qiagen
lysing agent) was added, the tube was briey vortexed manually, and then the tubes were secured
to an adapter to be vortexed at maximum speed for 10 minutes. The tubes were then centrifuged
at 1000 x g for 30 seconds, and the supernatant was transferred to a 2 mL collection tube. 250 µL
of solution C2 (Qiagen precipitating agent) was added to the collection tubes, which were then
vortexed for 5 seconds and then incubated on ice for 5 minutes. Tubes were then centrifuged for
60 seconds at 10,000 x g, and 750 µL of supernatant was transferred to clean 2 mL collection
tubes. 200 µL of solution C3 (Qiagen precipitating agent) was added, and the tubes were briey
vortexed manually and incubated on ice for 5 minutes again. Following incubation, the tubes were
centrifuged at 10,000 x g for 60 seconds, 750 mL of supernatant was added to 2 mL collection
tubes, 1200 µL solution C4 was added, and tubes were vortexed for 5 seconds. 675 µL of this
solution was loaded into a Qiagen kit spin column and centrifuged at 10,000 x g for one minute
three times with ow through being discarded between centrifugations. 500 µL of solution C5 was
added to the spin column, which was centrifuged at 10,000 x g for 30 seconds and one minute with
ow through discarded between centrifugations. The spin columns were placed into clean 2 mL
collection tubes, 100 µL nuclease-free water was added to the center of the spin column's white
lter membranes, and the samples were allowed to incubate at room temp for 5 minutes. Tubes
were centrifuged for 30 seconds at 10,000 x g to elute the DNA, spin columns were discarded, and
samples were checked for DNA quantication with a Qubit uorometric quantication meter on
the broad range detection setting. DNA was fragmented and tagged with a 615f/806r adapted
sequence before polymerase chain reaction amplication. Samples were sequenced using Nextera
MiSeq, and sequences were obtained from Illumina and Swift Biosciences.
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2.7.2 Microbiome Analysis
Microbiome bioinformatics analysis was performed with QIIME2 2020.2 [121]. Sequences were
imported and demultiplexed utilizing the Import as Casava option of q2-demux. The resulting
sequences were denoised, chimera-sorted via consensus chimera sorting, and clutered into OTUs at
97% similarity using q2-DADA2 [139]. Sequences were aligned, and a phylogeny was created using
q2-phylogeny [140, 141, 142]. Alpha and beta diversity analyses were performed using the core
diversity pipeline of q2-diversity after samples were rareed to 23,600 sequences per sample
[143, 144, 145, 146, 147, 148]. Alpha diversity statistical signicance was tested via Spearman's
correlation for numerical metadata and Kruskal-Wallis ANOVA for categorical data
[129, 149, 150, 151, 152, 130, 128]. A mantel test was used to analyze beta diversity dierences
between samples' distance matrices, and statistical signicance was tested via Spearman's
correlation for numerical metadata and PERMANOVA for categorical data
[153, 154, 155, 156, 134, 135, 131, 133]. Visualizations and Principle Coordinate Analysis plots
were generated via the q2-diversity plugin [157, 158, 159, 160]. Taxonomy was assigned via the
q2-feature-classier plugin using a naïve Bayes classier trained on the Silva 132 99% OTUs
515F/806R supplied by QIIME2 [161, 162, 163, 164, 165]. q2-composition plugin was used to
collapse the feature table for an analysis of community of microbiomes (ANCOM) test to detect
dierential abundances in dierent BMI categories and the treatment groups before and after
supplementation [166, 167].
3 Results
3.1 Alpha Diversity
3.1.1 BMI
Alpha diversity metrics dierences were not statistically signicant (p > 0.05) between BMI
classication groups normal vs overweight, normal vs obese, normal vs overweight + obese (Figure
1).
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(a) (b)
(c) (d)
Figure 1: BMI Classication (x-axes) plotted against y-axes Shannon's diversity (a), Observed
OTUs (b), Faith's phylogenetic diversity (c), and Pielou's evenness (d). Full-size gures can be
found in Figures 21-24 of the appendix.
3.1.2 Intervention
Alpha diversity did not signicantly change over the course of the study for both the placebo
and experimental groups. Interestingly, there were signicant dierences in alpha diversity metrics
between the placebo and experimental groups, independent of the eects of Glutenshield
supplementation (Faith p=0.000032, Observed OTUs p=0.0000018, Shannon p=0.000094).
Pielou's Evenness was not signicantly dierent between any groups (p > 0.05) (Figure 2-5).
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Figure 2: Observed OTUs (y-axis) for experimental and control groups before and after
Glutenshield supplementation. Dots represent statistical outliers.
Figure 3: Shannon's diversity index (y-axis) for experimental and control groups before and after
Glutenshield supplementation. Dots represent statistical outliers.
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Figure 4: Faith's phylogenetic diversity (y-axis) for experimental and control groups before after
Glutenshield supplementation.
Figure 5: Pielou's Evenness (y-axis) for experimental and control groups before and after
Glutenshield supplementation. Dots represent statistical outliers.
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3.1.3 Immune Markers
Richness and evenness metrics were negatively correlated with serum IgG4 levels (Shannon
rs=-0.46, p=0.0022; OTUs rs=-0.38 p=0.014; Faith rs=-0.32, p=0.042; Pielou rs=-0.41,
p=0.0067) (Figure 6). Shannon's diversity (rs=0.37, p=0.0477) and Pielou's evenness correlated
with serum IgM (rs=0.34, p=0.028) (Figure 7). IL-2 correlated with the number of observed
OTUs per sample (rs=0.314, p=0.0426). IgG1, IgG2, IgG3, IgA, IL-6, IL-8, and TNF-α did not
correlate with any alpha diversity metrics (p>0.05) (Figures 6, 7).
(a) (b)
(c) (d)
Figure 6: IgG4 (x-axes) plotted against y-axes of Shannon's diversity index (a), Observed OTUs
(b), Faith's phylogenetic diversity (c), and Pielou's evenness (d). One dot represents one
sequencing sample, with two sequencing samples per fecal sample.
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(a) (b)
Figure 7: IgM (x-axes) plotted against y-axes Shannon's diversity index (a) and Pielou's evenness
(b). One dot represents one sequencing sample, with two sequencing samples per fecal sample.
3.1.4 Fecal Fiber and Protein
Faith's phylogenetic diversity positively correlated with total dietary ber present in the fecal
matter (rs=0.304, p=0.05). Fecal crude protein correlated with Pielou's evenness (rs=0.321,
p=0.043) (Figure 8).
(a) (b)
Figure 8: Total dietary ber present in feces (x-axis) plotted against y-axis Faith's phylogenetic
diversity (a); crude protein present in feces (x-axis) plotted against y-axis Pielou's Evenness (b).
One dot represents one sequencing sample, with two sequencing samples per fecal sample.
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3.1.5 Fecal SCFA
The percent of the area under the curve (%AUC) of acetate correlated with Pielou's evenness
(rs=0.3530, p=0.0218). Propionate %AUC was strongly negatively correlated with richness and
evenness (Shannon rs=-0.6137, p=0.0000; OTUs rs=-0.6298; Faith rs=-0.5704, p=0.0001; Pielou
rs=-0.4038, p=0.008) (Figure 9). Isobutyrate %AUC correlated with qualitative measures of
richness (OTUs rs=0.3660, p=0.0171; Faith rs=0.3449, p=0.0253) (Figure 10). Valerate %AUC
correlated with observed OTUs (rs=0.3475, p=0.021), and isovalerate %AUC correlated with
Faith's phylogenetic diversity (rs=0.3066, p=0.0483) (Figure 10). Caproate %AUC strongly
correlated with richness but not evenness (Shannon's diversity rs=0.5117, p=0.0005; OTUs
rs=0.6679, p<0.0001; Faith rs=0.5142, p=0.0005; Pielou p>0.05) (Figure 11).
(a) (b)
(c) (d)
Figure 9: Propionate %AUC (x-axes) vs y-axes Shannon's diversity (a), Observed OTUs (b),
Faith's phylogenetic diversity (c), and Pielou's evenness (d). One dot represents one sequencing
sample, with two sequencing samples per fecal sample.
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(a) (b)
(c) (d)
Figure 10: Valerate %AUC (x-axis) plotted against y-axis observed OTUs (a); isobutyrate %AUC
(x-axis) plotted against y-axes observed OTUs (b) and Faith's phylogenetic diversity (c);
isovalerate %AUC (x-axis) plotted against y-axis Faith's phylogenetic diversity (d). One dot
represents one sequencing sample, with two sequencing samples per fecal sample.
Concentrations of fecal SCFA did not correlate as strongly as %AUC, as evidenced by fewer
signicant correlations and lower Spearman's rho values. Propionate and isobutyrate
concentrations negatively correlated with evenness (rs=-0.3058, p=0.0489; rs=-0.3178, p=0.0403).
Caproate concentrations, like AUC, did correlate with richness but not with evenness (Shannon
rs=0.4684, p=0.0018; OTUs rs=0.6355, p<0.0001; Faith rs=0.515, p=0.0005).
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(a) (b)
(c) (d)
Figure 11: Caproate %AUC (x-axes) plotted against y-axes Shannon's diversity (a), Observed
OTUs (b), Faith's phylogenetic diversity (c); Acetate %AUC (x-axis) plotted against y axis
Pielou's Evenness (d). One dot represents one sequencing sample, with two sequencing samples
per fecal sample.
(a) (b)
Figure 12: Propionate concentration (a) plotted against y-axis Pielou's Evenness (a); isobutyrate
concentration (x-axis) plotted against Pielou's Evenness (b). One dot represents one sequencing
sample, with two sequencing samples per fecal sample.
3.1.6 Gastrointestinal Symptoms
Richness and evenness were negatively correlated with heartburn (Shannon rs=-0.504,
p=0.0007; OTUs rs=-0.4494, p=0.0028; Faith rs=-0.4016; Pielou rs=-0.4216, p=0.0054). Urgent
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need for defecation negatively correlated with Shannon's diversity index (rs=-0.3672, p=0.0167)
and Faith's phylogenetic diversity (rs=-0.3317, p=0.0319). Feelings of incomplete evacuation
positively correlated with all metrics of richness (Shannon rs=0.5668, p=0.0001; OTUs rs=0.5298,
p=0.0003; Faith rs=0.6026, p<0.0001). Eructation positively correlated with observed OTUs
(rs=0.3103, p=0.0455). No alpha diversity metrics correlated with acid regurgitation, bloating,
nausea and vomiting, abdominal distension, increased gas, passage of stools, loose/hard stools, or
the sum of all GI symptoms (p>0.05).
(a) (b)
(c) (d)
Figure 13: Heartburn (x-axes) plotted against y-axes Shannon's diversity (a), Observed OTUs (b),
Faith's phylogenetic diversity (c); Acetate %AUC (x-axis) plotted against y-axis Pielou's Evenness
(d). One dot represents one sequencing sample, with two sequencing samples per fecal sample.
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(a) (b)
Figure 14: Urgent need for defecation (x-axes) plotted against y-axes Shannon's diversity index
(a) and Faith's phylogenetic diversity (b). One dot represents one sequencing sample, with two
sequencing samples per fecal sample.
(a) (b)
(c) (d)
Figure 15: Feelings of incomplete evacuation (x-axes) plotted against y-axes Shannon's diversity
(a), Observed OTUs (b), and Faith's phylogenetic diversity (c); eructation (x-axis) plotted against
y-axis observed OTUs (d). One dot represents one sequencing sample, with two sequencing
samples per fecal sample.
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(a)
(b)
Figure 16: Principle Coordinate Analysis (PCoA) plots based on Jaccard (a) and Bray-Curtis (b)
generated distance matrices. Black points represent obese participants, grey represent overweight,
and white represent normal BMI. Axes were chosen to represent as much variation as possible,
and distances between points represent Euclidean distance. One point represents one sequencing
sample, with two sequencing samples per fecal sample.
3.2 Beta Diversity
3.2.1 BMI
Signicant dierences were seen between BMI Classication groups for Jaccard distance,
Bray-Curtis distance, and unweighted UniFrac but not for weighted Unifrac. Signicant
dierences were seen from normal to overweight BMI groups (Jaccard p=0.001; Bray-Curtis
p=0.001; unweighted UniFrac p=0.013), normal to obese (Jaccard p=0.001; Bray-Curtis p=0.001;
unweighted UniFrac p=0.005), overweight to obese (Jaccard p=0.001; Bray-Curtis p=0.002;
unweighted UniFrac p=0.016), and normal to overweight and obese combined (Jaccard p=0.001;
Bray-Curtis p=0.001; unweighted UniFrac p=0.011).
3.2.2 Intervention
No metrics of beta diversity showed signicant changes with Glutenshield or placebo
supplementation (p>0.05).
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3.2.3 Immune Markers
IgG1 correlated with Jaccard distance (rs=0.17, p=0.012), and IgG3 correlated with
unweighted UniFrac distance (rs=0.156, p=0.047). IgG4 correlated with Jaccard distance
(rs=0.1878, p=0.013) and unweighted UniFrac distance (rs=0.1368, p=0.032). IgA correlated
with weighted UniFrac distance (rs=0.2637, p=0.001), as did IL-8 (rs=0.3064, p=0.001). IL-6
correlated with Bray-Curtis distance (rs=0.1764, p=0.002).
3.2.4 Fecal Fiber and Protein
Insoluble dietary ber content in the feces correlated with unweighted UniFrac distance
(rs=0.1482, p=0.04). Soluble and total dietary ber content in feces correlated with weighted
UniFrac distance (rs=0.3526, p=0.001; rs=0.1463, p=0.015). Protein did not correlate with any
beta diversity metrics (p>0.05)
3.2.5 Fecal SCFA
Acetate %AUC correlated with qualitative beta diversity metrics Bray-Curtis (rs=0.1389,
p=0.025) and weighted UniFrac (rs=0.2949, p=0.001). Propionate %AUC correlated with all
metrics of beta diversity (Jaccard rs=0.141, p=0.013; Bray-Curtis rs=0.4910, p=0.001;
unweighted UniFrac rs=0.4016, p=0.001; weighted UniFrac rs=0.2104, p=0.001). Butyrate
%AUC correlated with multiple measures of beta diversity (Jaccard rs=0.1656, p=0.003;
Bray-Curtis rs=0.1413, p=0.007; weighted UniFrac rs=0.1521, p=0.007). Weighted UniFrac
correlated with caproate %AUC (rs=0.1241, p=0.044).
Propionate concentration correlated with Jaccard distance (rs=0.1411, p=0.013), Bray-Curtis
(rs=0.1892, p=0.004), and weighted UniFrac (rs=0.2649, p=0.002). Weighted UniFrac also
correlated with butyrate (rs=0.1707, p=0.003), isobutyrate (rs=0.3475, p=0.001), valerate
(rs=0.4015, p=0.001), and isovalerate (rs=0.3338, p=0.001) concentrations.
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Figure 17: Rotated views of the same weighted UniFrac distance matrix PCoA plot. Darker
points represent higher %AUC propionate. Axes were chosen to represent as much variation as
possible, and distances between points represent Euclidean distance. One point represents one
sequencing sample, with two sequencing samples per fecal sample.
3.2.6 Gastrointestinal Symptoms
Multiple gastrointestinal symptoms correlated with beta diversity metrics. Quantitative
metrics Bray-Curtis and weighted UniFrac distance correlated with Heartburn (rs=0.3192,
p=0.002; rs=0.1272, p=0.044). Phylogenetic metrics correlated with acid regurgitation
(unweighted UniFrac rs=0.2364, p=0.01; weighted UniFrac rs=0.1799, p=0.02). Jaccard,
Bray-Curtis, and unweighted UniFrac correlated with bloating (rs=0.3098, p=0.001; rs=0.2328,
p=0.005; rs=0.2763, p=0.001). Bray-Curtis correlated with nausea and vomiting (rs=0.2494,
p=0.012). All metrics correlated with abdominal distension(Jaccard rs=0.2030, p=0.006;
Bray-Curtis rs=0.2045, p=0.007; unweighted UniFrac rs=0.2056, p=0.003; weighted UniFrac
rs=0.1250, p=0.016) Quantitative metrics correlated with eructation (Bray-Curtis rs=0.1615,
p=0.026; weighted UniFrac rs=0.2750, p=0.002). All metrics correlated with increased gas
(Jaccard rs=0.3130, p=0.001; Bray-Curtis rs=0.2512, p=0.003; unweighted UniFrac rs=0.2884,
p=0.001; weighted UniFrac rs=0.1563, p=0.015)
3.3 Taxonomy
The following taxonomy bar plots were generated using QIIME2:
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Figure 18: Taxonomic classication at the phylum level
Figure 19: Taxonomic classication at the class level
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Figure 20: Taxonomic classication at the order level
3.4 Dierential Abundances
Feaecalibacterium prausnitzii was found to be dierentially abundant between BMI
classication groups, with the highest abundance in the normal group and lowest abundance in
the obese group (F=19.23, W=376). No other dierentially abundant taxa showed trended from
normal to obese BMI. At the species level, two members of the genus Ruminoclostridium were
found to be dierentially abundant, increasing more in the Glutenshield group than the placebo
group (F=19.02, W=321; F=17.91, W=275). Members of the genus Bidobacterium were also
found to be dierentially abundant, increasing more in the placebo supplementation group
(F=12.21, W=176).
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4 Discussion
4.1 BMI
The lack of dierence in alpha diversity between BMI groups contrasts portions of the
literature showing a negative correlation between alpha diversity and BMI [168, 169, 170].
However, studies demonstrating that link have had a much larger sample size than this one, or
they have been performed with more controlling factors, such as using obese and lean twins [169].
This should serve as a reminder that though obesity is associated with chronic inammation,
metabolic disorders, and a microbiota trending toward dysbiosis, it is most directly a result of
caloric imbalance [171]. However, the dierences in beta diversity show evidence that dierent
BMI groups have separate microbiome proles, which does coincide with much of the literature
[168, 169, 170]. The increased abundance of Faecalibacterium prausnitzii as BMI trended toward
the normal group supports an association between F prausnitzii and a healthy weigh, but other
studies have not shown consistent results. Results from other studies have demonstrated increased
F. prausnitzii in obese children, no relationship between F. prausnitzii and obesity in adults, and
decreased F. prausnitzii in obese individuals, so there is not a common consensus of the
connections between F. prausnitzii and obesity [172, 173, 174] . The lack of F. prausnitzii in the
microbiota of overweight and obese participants could suggest a potential mechanism for increased
inammation in obese individuals, as F. prausnitzii is a butyrate producer with anti-inammatory
properties [175, 176].
4.2 Intervention
Synbiotic supplementation did not yield signicant changes to alpha or beta diversity, which
could - at surface level - potentially cause one to believe it was an ineective. However, other
probiotic supplementation trials have shown supplementation to modify certain taxa without
modifying the large-scale diversity of the microbiota [177]. The results of Webb et al 2019
demonstrated eectiveness of Glutenshield in this study for reducing IgG2 and bloating,
suggesting that these results can be achieved without signicantly modifying the microbiota
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diversity, potentially by mechanisms such as antigen exposure without colonization. There is the
possibility that due to manufacturing or structural issues with the probiotic, strains may not have
been alive by the time the reached the colon, and these issues should be brought into question. It
is known that even attenuated microbes of certain taxa can trigger physiological responses,
especially members of the Lactobacillus and Bidobacterium genera, which were included in
Glutenshield [178, 179, 180]. Per the ANCOM results, Glutenshield supplementation did increase
the abundance of Ruminoclostridium in the experimental group but not the control group. Higher
abundances of Ruminoclostridium are found in patients without inammatory bowel disease
(IBD) compared to patients with IBD. Ruminoclostridium is in the family Ruminocaccae, which is
a family containing obligate anaerobes including Faecalibacterium, which tends to be positively
associated with health status [184].
One important factor that should be considered in future trials is the ller of the placebo
supplement, as this likely had an eect on the microbiota of the control group, based on the
dierential abundance results of the ANCOM. It was found that Bidobacterium were greatly
increased upon supplementation of micro-crystalline cellulose, a dietary ber, in the placebo
group but not the Glutenshield group. Cellulose and cellodextrins (products of incomplete
degradation of cellulose by other microbes) can be broken down by Bidobacterium, and high
cellulose diets have been shown to increase the abundance of Bidobacterium in the gut
microbiota [181, 182, 183]. It is possible that the eects of the placebo supplement on
Bidobacterium could have attentuated signicant dierences in changes in immune markers and
symptoms between the control and experimental groups in Webb et al 2019 [136].
4.3 Immune Markers
The negative correlation between IgG4 and richness that was consistent across all metrics of
alpha diversity suggests a strong relationship between the diversity of taxa present and IgG4
levels. IgG4 plays a role in the etiology of autoimmune diseases, and it has been found to be
elevated in subsets of IBD patients [185]. Additionally, elevated IgG4 is associated with
microbiota trending toward dysbiosis [185]. The results of this study also showed that IgG4 levels
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correlated with qualitative metrics of beta diversity, suggesting that IgG4 elevation could be in
response to the presence of dierent microbial proles more dependent on presence and not as
dependent on abundance of the dierentially abundant taxa. Mechanistic links between
microbiome diversity and IL-2 and IgM are yet to be elucidated, and associations with one metric
of richness may not imply any causal relationship. The correlation of IgG1, IgG3, IgA, IL-6, and
IL-8 suggest that participants with increased immune activation have dierent microbial
communities compared to those with lower immune cytokine levels.
4.4 Fecal Fiber and Protein
Though the American Gut project found an association between the diversity of dietary ber
intake and alpha diversity, this study found a relationship between the total ber present in the
feces and Faith's phylogenetic diversity [17]. This relationship could exist due to increased total
ber intake potentially increasing the amount passed in the stool, and consumed ber diversity
may increase with increased total ber consumed. The beta diversity correlation with soluble,
insoluble, and total dietary ber shows evidence for dierent communities in the microbiota of
those with diering levels of ber in the feces. This could be a result of multiple factors, such as
recently altered ber intake, high ber intake, the lack of colonization by certain ber-degrading
species, or even faster transit time. It is known that dietary ber plays an important role in
shaping the gut microbiota, but this study did not control the many dimensions by which ber
intake can change [17].
Unfortunately, the relationship between fecal crude protein and evenness is not currently
understood. Though certain taxa can utilize amino acids that escape digestion in the small
intestine, microbial dynamics are complex, and more research is necessary to understand how the
amount of fecal protein that passes through the stool is associated with evenness of the
microbiome.
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4.5 Fecal SCFA
The portion of the total SCFA that were propionate was strongly shown to decrease as
richness decreased, suggesting that increased richness is associated with taxa that produce more
complex SCFA. Similarly, as richness increased, the production of more complex SCFA, such as
valerate, isovalerate, and caproate also increased, with caproate showing the strongest positive
correlation with alpha diversity. Caproate concentration also correlated with alpha diversity,
suggesting a potential application of caproate levels as a biomarker for alpha diversity in cases
where it may be more applicable to measure SCFA ratios or concentrations than to sequence the
microbiome. These results also supported another study showing that caproate and valerate levels
are associated with increased richness [108]. Beta diversity correlations suggest that unique
community structures are associated with varying amounts of each SCFA, which is supported by
the fact that specic bacterial taxa harbor unique enzymes that degrade certain bers to produce
specic metabolites. Dierent bacterial communities will contain varying abundances of taxa that
are capable of producing certain SCFA.
4.6 GI Symptoms
Many metrics of alpha and beta diversity were associated with gastrointestinal symptoms,
reinforcing the role of microbial communities inammatory bowel disease etiology. The inverse
relationship between heartburn and richness supports a microbiota trending toward dysbiosis
associating with the heartburn symptom presentation, which coincides with the high cooccurrence
of IBD, functional dyspepsia, and gastroesophageal reux disease [186].. It has been found that
esophageal microbiota changes are associated with heartburn and esophageal reux [187, 188].
However, since the gut microbiota and esophagus are separated by roughly 20 meters of small
intestine with frequent peristaltic contractions and a stomach with pH around 3.5, it is unlikely
that bacteria migrate from the gut microbiota to modulate the esophageal microbiome [189, 190].
There are multiple potential links between the gut microbiota and heartburn. One potential
mechanistic link between the gut microbiota and heartburn could be the gut-vagus nerve axis,
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which is a bidirectional (80% aerent) pathway that can be activated by specic microbial
metabolites or by gut endocrine cells [191]. The vagal pathway is one of the most prevalent
gut-brain axis pathways, and it also innervates the stomach and upper GI tract [192, 193].
Increased vagal activity is associated with esophageal acid reux, which can trigger
esophageal-cardiac reex arcs that contribute to both cardiac and non-cardiac related angina-like
chest pain [194, 193]. Another mechanism by which this could take place is by proton pump
inhibitors (PPI), a common type of medication to reduce heartburn symptoms, altering the gut
microbiota [195]. This study did not document the use of PPI by participants, which could have
caused the observed microbiome changes associated in participants with heartburn. The
correlation of beta diversity metrics with acid regurgitation and heartburn also suggest the
association of diering microbial communities with upper GI symptoms, which could be the result
of the aforementioned mechanisms.
Bloating and abdominal distension are symptoms of increased gas production in the small and
large intestines, predominantly CO2, H2, and CH4 [196]. The major source of intestinal gas is
bacterial fermentation of undigested particles such as bers and protein, and certain taxa are
more likely to produce these gases, whereas other taxa are more likely to consume them [196].
Thus, it follows that this study found dierences in the communities present with bloating,
abdominal distension, and increased gas. Future testing will utilize numerical metadata
dierential abundance analyses to further elucidate what bacterial communities are more
associated with gas and bloating.
The negative correlation between richness and urgent need to defecate and the positive
correlation between richness and feelings of incomplete evacuation coincide with the literature
characterizing the microbiota of constipated IBS patients (IBS-C). Though IBS patients generally
experience a dysbiosis that is associated with low richness, IBS-C patients tend to have higher
microbial richness and abundances [197, 198]. This is supported by studies demonstrating
decreased richness in individuals with fast transit time and increased richness in individuals with
slow transit time [199, 200].
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4.7 Limitations
This study was limited by a small sample size. Though Webb 2019 had 20 participants, only
the microbiomes of 11 participants (before and after) were able to be sequenced due to funding
[136]. Also, the nature of most of the variables measured was observational and not causal, other
than the eects of the placebo-controlled intervention. Limitations of the 16s microbiome analysis
should also be considered. Despite the evolution of high-throughput sequencing and analysis
techniques over the past 10 years, these methods do not fully reconstruct the microbiota of an
individual - they only provide a representation [201]. Though denoising and chimera sorting were
performed, these processes may not be perfect and may allow misreads and biases in the OTUs
identied or excluded [202].
4.8 Future Directions
Future directions for this research include performing Songbird analysis to identify
dierentially abundant taxa for numerical metadata that correlated with beta-diversity in an eort
to identify more specic dierences in the communities present. Doing so may help to elucidate
the microbiota changes associated with disease states, especially those of the gastrointestinal tract.
5 Conclusion
Overall, signicant dierences were found in community structure in participants with varying
BMI classication and certain immune markers, fecal ber, protein, and SCFA, and GI symptoms.
Metrics of richness and evenness were found to signicantly correlate with IgG4, IgM, IL-2,
acetate, propionate, isobutyrate, valerate, isovalerate, caproate, heartburn, urgent need to
defecate, and feelings of incomplete evacuation. Metrics of beta diversity distance between
samples demonstrated signicantly dierent community structure between normal and overweight,
normal and obese, and overweight and obese BMI classication groups. Additionally, signicant
dierences in community structure correlate with IgG1, IgG3, IgG4, IgA, IL-6, IL-8, fecal ber,
propionate, butyrate, heartburn, acid regurgitation, nausea and vomiting, bloating, abdominal
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distension, increased gas, and eructation. Though metrics of alpha and beta diversity were not
signicantly altered by synbiotic intervention, an ANCOM identied dierentially abundant
bacterial taxa dierentially abundant after supplementation. Bidobacterium were increased in
the placebo group, which could be a result of the placebo pill contents. The ANCOM also
identied taxa associated with BMI. Findings demonstrate alpha and beta diversity associations
with various SCFAs, GI symptoms, immune markers, and BMI. The results of the
placebo-controlled intervention suggest careful consideration of placebo contents moving forward.
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7 Appendix
Figure 21: BMI classication (x-axis) plotted against Shannon's diversity index (y-axis).
Figure 22: BMI classication (x-axis) plotted against observed OTUs (y-axis).
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Figure 23: BMI classication (x-axis) plotted against Faith's phylogenetic diversity (y-axis).
Figure 24: BMI classication (x-axis) plotted against Pielou's evenness (y-axis).
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